Interferon alpha in the treatment of chronic myelogenous leukemia
- PMID: 9883313
Interferon alpha in the treatment of chronic myelogenous leukemia
Abstract
Fifteen years ago Talpaz and colleagues were the first to determine that natural interferon alpha (INF-alpha) induces hematologic remission in chronic phase patients with chronic myeloid leukemia (CML). Further research revealed that this agent, contrarily to conventional chemotherapy with busulfan or hydroxyurea, eliminates leukemic hematopoietic cells having Philadelphia chromosome (Ph1-positive) in about 20% of patients, leading to the phase of cytogenetic remission. Comparison of the efficiency of IFN-alpha with conventional chemotherapy was carried out in several randomized clinical trials. It was found, that IFN-alpha delays the occurrence of blastic phase of CML and prolongs patients life span. It does not create, however, a likely chance of full recovery. The results of the randomized trails, carried out in France, showed that the combination of IFN-alpha and cytarabine as compared with INF-alpha alone, increases the rate of major cytogenetic response and prolongs survival in the chronic phase of CML. IFN-alpha efficiency in acceleration and blastic transformation phases of CML has not been proven so far, although this drug may be of certain value in combination with hydroxyurea or other cytostatic agents. At present, it is more often considered that IFN-alpha should be a first line therapy in newly diagnosed CML in its chronic phase, if due to absence of appropriate donors or advanced age, allogenic bone marrow transplantation cannot be performed.
Similar articles
-
Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.Int J Hematol. 2000 Aug;72(2):229-36. Int J Hematol. 2000. PMID: 11039674
-
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.Cancer. 2003 Dec 15;98(12):2636-42. doi: 10.1002/cncr.11831. Cancer. 2003. PMID: 14669283
-
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.Semin Oncol. 1994 Dec;21(6 Suppl 14):8-13. Semin Oncol. 1994. PMID: 7992099 Review.
-
[Chronic myeloid leukemia].Ther Umsch. 1996 Feb;53(2):82-7. Ther Umsch. 1996. PMID: 8629268 German.
-
[Recent progress in therapy for chronic myelogenous leukemia].Gan To Kagaku Ryoho. 1997 Jul;24(9):1066-73. Gan To Kagaku Ryoho. 1997. PMID: 9239158 Review. Japanese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical